1887

Abstract

Human parvovirus B19 is the aetiological agent of the common childhood disease erythema infectiosum (fifth disease). The infection is usually benign and self-limiting, but in adults cases of severe arthritis which may persist for years have been reported. Neutralizing antibodies directed against the structural proteins are usually produced shortly after the infection. The immune response against the third major protein, the nonstructural protein NS-1, of parvovirus B19 has not been characterized so far. We cloned and expressed the full-length NS-1 protein and fragments thereof in . The purified recombinant proteins were used to investigate the presence of antibodies to the NS-1 protein in sera from patients with parvovirus B19 infection. Specific antibodies could be detected in sera from patients suffering from severe parvovirus B19-associated arthritis using Western blot analysis and an ELISA. Sera from patients with acute or past infection without complications did not contain detectable levels of immunoglobulin to NS-1. The use of subfragments of the NS-1 protein allowed localization of the antigenic domains in the carboxy-terminal region of the protein.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-76-3-519
1995-03-01
2022-05-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/76/3/JV0760030519.html?itemId=/content/journal/jgv/10.1099/0022-1317-76-3-519&mimeType=html&fmt=ahah

References

  1. Anderson M. J., Jones S. E., Fisher-Hoch S. P., Lewis E., Hall S. M., Bartlett C. L. R., Cohen B. J., Mortimer P. P., Pereira M. S. 1983; Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet ii:1378
    [Google Scholar]
  2. Brown K. E., Anderson S. M., Young N. S. 1993; Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262:114–117
    [Google Scholar]
  3. Cassinotti P., Weitz M., Siegl G. 1993; Human parvovirus B19 infection: routine diagnosis by a new nested polymerase chain reaction assay. Journal of Medical Virology 40:228–234
    [Google Scholar]
  4. Cohen B. J., Buckley M. M., Clewley J. P., Jones V. E., Puttick A. H., Jacoby R. K. 1986; Human parvovirus infection in early rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases 45:832–838
    [Google Scholar]
  5. Cossart Y. E., Field A. M., Cant B., Widdows D. 1975; Parvovirus-like particles in human sera. Lancet i:72–73
    [Google Scholar]
  6. Cotmore S., McKie V. C., Anderson L. J., Astell C. R., Tattersall P. 1986; Identification of the major structural and non-structural proteins of human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. Journal of Virology 60:548–557
    [Google Scholar]
  7. Doerig C., Hirt B., Antonietti J. P., Beard P. 1990; Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. Journal of Virology 64:387–396
    [Google Scholar]
  8. Foto F., Sang K. G., Scharosch L. L., Howard E. J., Naides S. J. 1993; Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. Journal of Infectious Diseases 167:744–748
    [Google Scholar]
  9. Haist S., März J., Wolf H., Modrow S. 1992; Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-l-infected and uninfected humans. AIDS Research and Human Retroviruses 8:1909–1917
    [Google Scholar]
  10. Hoofnagle J. H., Duskeiko G. M., Seeff L. B., Bales Z. B., Waggoner J. G., Jones E. A. 1981; Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Annals of Internal Medicine 94:744–748
    [Google Scholar]
  11. Jawad A. S. M. 1993; Persistent arthritis after human parvovirus infection. Lancet 341:494
    [Google Scholar]
  12. Klouda P. T., Corbin S. A., Bradley B. A., Cohen B. J., Woolfe A. D. 1986; HLA and acute arthritis following human parvovirus infection. Tissue Antigens 28:318–319
    [Google Scholar]
  13. Koch W. C., Adler S. P. 1990; Detection of human parvovirus B19 DNA by using the polymerase chain reaction. Journal of Clinical Microbiology 28:65–69
    [Google Scholar]
  14. Kurtzman G. J., Frickhofen N., Kimball J., Jenkins D. W., Nienhuis A. W., Young N. S. 1989a; Pure red-cell aplasia due to persistent parvovirus B19 infection and its cure with immuno globulin therapy. New England Journal of Medicine 321:519–523
    [Google Scholar]
  15. Kurtzman G. J., Cohen B. J., Field A. M., Oseas R., Blease R. M., Young N. S. 1989b; Immune response to B19 parvovirus and an antibody defect in persistent viral infection. Journal of Clinical Investigation 84:1114–1123
    [Google Scholar]
  16. Liu J. M., Green S. W., Shimada T., Young N. S. 1992; A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. Journal of Virology 66:4686–4692
    [Google Scholar]
  17. Miller G., Grogan E., Rowe D., Rooney C., Heston L., Eastman R., Andiman W., Niederman J., Lenoir G., Henle W. 1987; Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein–Barr virus infection. Journal of Infectious Diseases 156:26–35
    [Google Scholar]
  18. Mori J., Beattie P., Melton D. W., Cohen B. J., Clewley J. P. 1987; Structure and mapping of the DNA of human parvovirus B19. Journal of General Virology 68:2797–2806
    [Google Scholar]
  19. Naides S. J., Scharosch L. L., Foto F., Howard E. J. 1990; Rheumatologic manifestations of human parvovirus B19 infection in adults. Arthritis and Rheumatism 33:1297–1309
    [Google Scholar]
  20. Ozawa K., Young N. 1987; Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. Journal of Virology 61:2627–2630
    [Google Scholar]
  21. Ozawa K., Ayub J., Kajigaya S., Shimada T., Young N. 1988; The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. Journal of Virology 62:2884–2889
    [Google Scholar]
  22. Patou G., Pillay D., Myint S., Pattison J. 1993; Characterization of a nested PCR assay for the detection of parvovirus B19. Journal of Clinical Microbiology 31:540–546
    [Google Scholar]
  23. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. 1981; Parvovirus infections and hypoplastic crisis in sickle-cell anemia. Lancet i:664–665
    [Google Scholar]
  24. Pont J., Puchhammer-Stöckl E., Chott A., Popow-Kraupp T., Kienzer H., Postner G., Honetz N. 1992; Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. British Journal of Haematology 80:160–165
    [Google Scholar]
  25. Reid D. M., Reid T. M. S., Brown T., Rennie J. A. N., Eastmond C. J. 1985; Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet i:422–425
    [Google Scholar]
  26. Saikawa T., Anderson S., Momoeda M., Kajigaya S., Young N. S. 1993; Neutralizing epitopes of B19 parvovirus cluster in the VP1 and VP1-VP2 junction regions. Journal of Virology 67:3004–3009
    [Google Scholar]
  27. Salimans M. M. M., Van Bussel M. J. A. W. M., Brown C. S., Spaan W. J. M. 1992; Recombinant parvovirus B19 capsids as a new substrate for detection of B 19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assay. Journal of Virological Methods 39:247–258
    [Google Scholar]
  28. Sato H., Hirata J., Fürukawa N., Kuroda H., Shiraki Y., Maeda Y., Okochi K. 1991a; Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19. Journal of Virology 65:1667–1672
    [Google Scholar]
  29. Sato H., Hirata J., Kuroda H., Shiraki Y., Maeda Y., Okochi K. 1991b; Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. Journal of Virology 65:5845–5849
    [Google Scholar]
  30. Serjeant G. R., Serjeant B. E., Thomaas P. W., Anderson M. J., Patou G., Pattison J. R. 1993; Human parvovirus infection in homozygous sickle cell disease. Lancet 341:37–40
    [Google Scholar]
  31. Shade R. O., Blundell M. L., Cotmore S. F., Tattersall P., Astell C. R. 1986; Nucleotide sequence and genome organisation of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of Virology 58:921–936
    [Google Scholar]
  32. Towbin H., Staehlin T., Gordon J. 1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, USA 76:4350–4354
    [Google Scholar]
  33. Ueno Y., Umadome H., Shimodera M., Kishimoto I., Ikegaya K., Yamauchi T. 1993; Human parvovirus B19 and arthritis. Lancet 341:1993
    [Google Scholar]
  34. White D. G., Mortimer P. P., Blake D. R., Woolf A. D., Cohen B. J., Bacon P. A. 1985; Human parvovirus arthropathy. Lancet i:419–421
    [Google Scholar]
  35. Yoshimoto K., Rosenfeld S., Frickhofen N., Kennedy D., Kajigya S., Young N. S. 1991; A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response. Journal of Virology 657056–7060
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-76-3-519
Loading
/content/journal/jgv/10.1099/0022-1317-76-3-519
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error